Publication & Citation Trends
Publications
0 total
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia OA
Cited by 13
Semantic Scholar
Abstract 940: The combinatorial activity of Eftozanermin ABBV621, a novel and potent TRAIL receptor agonist fusion protein, in pre-clinical models of hematologic malignancies
Cited by 0
Semantic Scholar
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors. OA
Cited by 3
Semantic Scholar
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors OA
Cited by 29
Semantic Scholar
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor OA
Cited by 106
Semantic Scholar
The Combinatorial Activity of Eftozanermin (ABBV-621), a Novel and Potent TRAIL Receptor Agonist Fusion Protein, in Pre-Clinical Models of Hematologic Malignancies OA
Cited by 3
Semantic Scholar
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies OA
Cited by 60
Semantic Scholar
Quantification of BCL-2 Family Members by Flow Cytometry.
Cited by 2
Semantic Scholar
Research Topics
Cell death mechanisms and regulation
(20)
Chronic Lymphocytic Leukemia Research
(8)
Bioactive Compounds and Antitumor Agents
(8)
Synthesis and Characterization of Heterocyclic Compounds
(8)
Signaling Pathways in Disease
(7)
Affiliations
Research Triangle Park Foundation
RTI International
AbbVie (United States)
University of Chicago
University of Colorado Health